See what questions
a doctor would ask.
Acute myeloid leukemia is a bone marrow and blood cancer where immature white blood cells multiply out of control. The cancer is generally aggressive and has a high risk of recurrence. Old patients who cannot cope with standard chemotherapy or patients who stop responding to it may be able to achieve survival benefits by using the anti-cancer drug Zarnestra (tipifarnib). The drug is still undergoing clinical trials. Results from a recent trial reported that of elderly subjects who didn't undergo chemotherapy, 34% showed a positive anti-cancer response and 18% had a complete response for an average of 6.4 months. The average survival rate for those with a complete response was 14.4 months compared to 3.1 months for those with no response. The main side effects of the therapy were infection and gastrointestinal disorders. 18% of subjects were hospitalized because of side effects and the death rate for the treatment was 5%.
Source: summary of medical news story as reported by Cancer Consultants
About: Anti-cancer drug may help acute myeloid leukemia sufferers who can't tolerate chemotherapy
Date: 15 December 2004
Source: Cancer Consultants
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City